UNIC
SFDR Classification
SFDR 8

Lyxor MSCI Disruptive Technology ESG Filtered (DR) UCITS ETF - Acc

ISR Label
Latest NAV
13.4571 USD
Performance YTD

-18.61%

Assets Under Management
219m USD
TER
0.45%
ISIN
LU2023678282
Dividend Policy
Capitalisation
Investment Objective

The Lyxor MSCI Disruptive Technology ESG Filtered (DR) UCITS ETF - Acc is a UCITS compliant exchange traded fund that aims to track the MSCI ACWI IMI Disruptive technology ESG Filtered Index. The index aims to represent the performance of companies expected to derive significant revenue from areas like 3D printing, the ‘Internet of Things’, cloud computing, Fintech, digital payments, healthcare, robotics, clean energy and smart grids, and cybersecurity. The index methodology employs a set of key words of theme-related products, services and concepts built using natural language processing and data analysis techniques. These key words help identify relevant companies based on the proportion of revenue that can be linked to the Disruptive Technology theme. Annually, the expression of the high-level index objective and associated sub-themes are reviewed with the consultative input of a thematic industry expert retained by MSCI. The index is filtered based on MSCI ESG Ratings, controversy scores and certain business activities, with final stock weights based on a combined score of three fundamental metrics: 1-year sales growth, Return on Invested Capital, and % sales spent on R&D and Capex. Lyxor ETFs are efficient investment vehicles listed on exchange that offer transparent, liquid and low-cost exposure to the underlying benchmark index.

As announced in March 2020, effective October 1st, 2021, the TER was reset to its target level of 0.45%.

UNIC
SFDR Classification
SFDR 8

Lyxor MSCI Disruptive Technology ESG Filtered (DR) UCITS ETF - Acc

ISR Label

PERFORMANCE

Performance history

Legend:

The figures relating to [past performances / simulated past performances / past performances and simulated past performances] refer or relate to past periods and are not a reliable indicator of future results. This also applies to historical market data.

Product 1Y
Lyxor MSCI Disruptive Technology ESG Filtered (DR) UCITS ETF - Acc -23.34%
Benchmark Index -22.84%
Data as of 27/01/2022, Source: Lyxor International Asset Management
Product YTD 1M 3M 1Y 3Y 5Y 10Y ALL
Lyxor MSCI Disruptive Technology ESG Filtered (DR) UCITS ETF - Acc -18.61% -19.51% -21.36% -23.34% - - - 40.11%
Benchmark Index -18.59% -19.59% -21.27% -22.84% - - - 41.26%
Data as of 27/01/2022, Source: Lyxor International Asset Management
Product 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Lyxor MSCI Disruptive Technology ESG Filtered (DR) UCITS ETF - Acc 1.79% - - - - - - - - -
Benchmark Index 2.38% - - - - - - - - -
Data as of 27/01/2022, Source: Lyxor International Asset Management

NAV History

Date NAV Currency Fund AUM
27/01/2022 13.4571 USD 214m USD
26/01/2022 13.781 USD 219m USD
25/01/2022 13.8739 USD 221m USD
24/01/2022 14.2096 USD 226m USD
21/01/2022 14.1529 USD 225m USD

Dividend History

This fund does not distribute any dividend.

HOLDINGS

This ETF uses physical replication to track the performance of the index. As such, the holdings of the ETF reflect those of the benchmark index.
You can read more about our approach to replication in our pragmatic guide to replication.

Name Currency Weight Sector Country
MIRATI THERAPEUTICS INC USD 1.85% Health Care United States
ANAPTYSBIO INC USD 1.73% Health Care United States
FATE THERAPEUTICS INC USD 1.51% Health Care United States
FULGENT GENETICS INC USD 1.35% Health Care United States
SYMANTEC CORP USD 1.26% Information Technology United States
CITRIX SYSTEMS INC USD 1.24% Information Technology United States
IDORSIA LTD CHF 1.24% Health Care Switzerland
PROTHENA CORP PLC USD 1.17% Health Care Ireland
Apple Inc USD 1.16% Information Technology United States
Inovio Pharmaceuticals Inc USD 1.09% Health Care United States
Name Listing Currency Quantity Weight Sector Country
MIRATI THERAPEUTICS INC USD 35,915 1.85% Health Care United States
ANAPTYSBIO INC USD 120,958 1.73% Health Care United States
FATE THERAPEUTICS INC USD 84,535 1.51% Health Care United States
FULGENT GENETICS INC USD 47,799 1.35% Health Care United States
SYMANTEC CORP USD 109,146 1.26% Information Technology United States
CITRIX SYSTEMS INC USD 26,596 1.24% Information Technology United States
IDORSIA LTD CHF 117,848 1.24% Health Care Switzerland
PROTHENA CORP PLC USD 75,884 1.17% Health Care Ireland
Apple Inc USD 15,967 1.16% Information Technology United States
Inovio Pharmaceuticals Inc USD 606,424 1.09% Health Care United States

This funds does not use sec/lending

Index Information

Full Name MSCI ACWI IMI Disruptive Technology ESG Filtered Net Total Return Index
Index Type Performance
Index Bloomberg Ticker MXACDSRT
Index Currency USD
Number of Index Components 212
Further Information www.msci.com
Dividend Yield (%) 0.63
Data as of 26/01/2022

Index Composition Breakdown

Currency Breakdown

USD 75.38%
EUR 10.56%
CHF 3.64%
CAD 2.52%
Others 2.37%
HKD 1.59%
AUD 1.45%
CNH 1.02%
JPY 0.8%
GBP 0.68%

Sector Breakdown

Information Technology 50.77%
Health Care 35.22%
Industrials 5.31%
Utilities 3.44%
Communication Services 2.8%
Consumer Discretionary 1.26%
Financials 0.68%
Energy 0.39%
Materials 0.12%

Countries Breakdown

United States 72.19%
China 4.8%
Switzerland 3.93%
Germany 3.35%
France 2.33%
Canada 2.01%
Netherlands 1.66%
Belgium 1.54%
Ireland 1.17%
Australia 0.84%
Puerto Rico 0.83%
Japan 0.8%
United Kingdom 0.68%
Spain 0.67%
Taiwan 0.67%
Sweden 0.64%
New Zealand 0.6%
Denmark 0.58%
Thailand 0.28%
Italy 0.24%
Brazil 0.21%
Data as of 26/01/2022, Source: Lyxor International Asset Management

CHARACTERISTICS

Main Fund Characteristics

ISIN LU2023678282
UCITS Yes
Share Class Currency USD
Assets Under Management 219.3m USD
Total Expense Ratio 0.45%
Dividend Treatment Capitalisation
EU-SD Status Out of Scope
Fund Type SICAV
Domicile Luxembourg
Replication Method Direct (Physical)
Sampling No
Securities Lending No
Umbrella AUM 15,657.7m USD
ISA Yes
SIPP Yes
German Tax Transparency No
Financial Year End 31/10/2022
Portfolio Managers Raphaël Dieterlen, Salah BENAISSSA
UKFRS Yes
Inception Date 02/03/2020
Minimum Investment 1 Share
SFDR Classification 8

DISCLAIMER: This fund includes a risk of capital loss. Investors therefore may not recover all or part of their initial investment. The redemption value of this fund may be less than the amount initially invested. In a worst case scenario, investors could sustain the loss of their entire investment. Be sure to read carefully the Key Investor Information document, and the “risk factors” section of a fund’s performance to better understand the risks involved.

Trading Information

Exchange Ticker Bloomberg Listing Currency Currency Hedged Listing Date Dividend Policy ADV 3M ISIN Fund AUM in CCY
LSE DTEC LN GBP - 30/04/2020 Capitalisation 40,366GBP LU2023678282 162m GBP
LSE UNIC LN USD - 30/04/2020 Capitalisation 57,238USD LU2023678282 219m USD
BMV UNICN MM MXN - 18/05/2021 Capitalisation - LU2023678282 4,528m MXN
Xetra DRUP GY EUR - 30/04/2020 Capitalisation 388,814EUR LU2023678282 194m EUR
Borsa Italiana UNIC IM EUR - 30/04/2020 Capitalisation 869,764EUR LU2023678282 194m EUR
SIX Swiss Ex QBIT SW CHF - 23/04/2020 Capitalisation 21,586CHF LU2023678282 202m CHF
Euronext UNIC FP EUR - 21/04/2020 Capitalisation 105,937EUR LU2023678282 194m EUR
*Related Shareclasses

Market Makers

Flow Traders
Optiver
Société Générale
Data provided by relevant exchanges

Passporting Information

UK
Spain
France
Germany
Belgium
Netherlands
Italy
Switzerland
Luxembourg
Austria
Sweden
Finland
Norway
Denmark
Korea
Data as of 27/01/2022, Source: Lyxor International Asset Management

NEWS

Corporate
03/11/2021

Corporate ESG @ Lyxor ETF – our new digital handbook

Lyxor in the Media
19/10/2021

Lyxor in the Media Video: Lyxor’s sustainable thematic ETFs

Blog
15/04/2021

Blog Disruptive Technology vlog: invest in tomorrow’s giants, today

Notice to Shareholders
28/01/2021

Notice to Shareholders Annual general meeting of Lyxor Index Fund

We have a new home

Banner Amundi

Read more